NICE Publishes Positive Draft Guidance on DySIS Cervical Cancer Screening Product
News Apr 05, 2012
DySIS Medical Ltd has announced that the National Institute for Health and Clinical Excellence (‘NICE’) has published draft guidance on its DySIS cervical cancer screening product for public consultation.
DySIS colposcopy uses spectral imaging techniques during the course of a normal examination to highlight to clinicians any areas of concern by mapping the condition of a woman’s cervix.
In clinical trials, it has been shown to significantly boost sensitivity in detecting cervical cancer in its earliest stages.
Armed with this additional information, clinicians are able to take immediate steps to treat patients and prevent disease progression.
The provisional recommendation of NICE’s Diagnostic Advisory Committee was: “DySIS is a cost-effective option for examining the uterine cervix in women referred for colposcopy and should be considered in procurement plans when replacing colposcopy equipment.”
Commenting on the announcement, Miss Theresa Freeman Wang, Consultant Gynaecologist MRCOG, Whittington Hospital, who has been using DySIS, said “The extra sensitivity that DySIS delivers could be very helpful in detecting the smaller pre-cancerous lesions that require treatment and may assist in safely reducing the need for Colposcopy follow up appointments.”
The report also noted: “The sensitivity of DySIS remained high (77.4%) in the subgroup of women referred to colposcopy with low-grade cytology, whereas the sensitivity of conventional colposcopy was low (19.4%).”
A higher sensitivity in detecting cervical changes as early as possible implies a reduced cost burden to healthcare systems.
The NICE paper stated: “The Committee concluded that the modelling of DySIS colposcopy showed that it was robustly cost effective (possibly even cost saving) when compared with conventional colposcopy.”
Specifically the draft guidance stated, “The base case indicates that standard colposcopy was more expensive and less effective [than DySIS].”
Alastair Atkinson, CEO of DySIS Medical said: “Today’s encouraging draft guidance from NICE coupled with an extremely positive response to our recent US launch are key milestones for the company. An important feature of the report is the acknowledgement that DySIS delivers a higher standard of care for women at a lower overall cost, and this is supported by our observations in other key international markets.”
The consultation document can be viewed in full at: http://guidance.nice.org.uk/DT/5 and a final decision will be made in May 2012 following a public consultation period.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE
Scientists Reveal the Relationship Between Sugar and CancerNews
By analysisng metabolites scientists have clarified how the Warburg effect, a phenomenon in which cancer cells rapidly break down sugars, stimulates tumor growth.READ MORE